Akebia Therapeutics

Akebia Therapeutics is a pharmaceutical company, which focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The Company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme.
Company Growth (employees)
Cambridge, US
Size (employees)
90 (est)
Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, US

Akebia Therapeutics Office Locations

Akebia Therapeutics has an office in Cambridge
Cambridge, US (HQ)
1100 245 First St

Akebia Therapeutics Data and Metrics

Akebia Therapeutics Financial Metrics


Net income (Q1, 2017)

(44.5 m)

EBIT (Q1, 2017)

(45 m)

Market capitalization (21-Sep-2017)

715.2 m

Cash (31-Mar-2017)

87.3 m
Akebia Therapeutics's current market capitalization is $715.2 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

25.4 m43 m115.8 m

General and administrative expense

12.5 m18.5 m22.2 m

Operating expense total

37.9 m61.5 m138 m


(37.9 m)(61.5 m)(136.5 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

7.5 m7.2 m15.8 m20.2 m30.9 m31.2 m60 m

General and administrative expense

3.4 m3.7 m3.9 m5.8 m5.3 m4.9 m5.8 m

Operating expense total

10.9 m10.9 m19.7 m26 m36.2 m36.2 m65.8 m


(10.9 m)(10.9 m)(19.7 m)(26 m)(36.2 m)(36.2 m)(45 m)
USDFY, 2014FY, 2015FY, 2016


32.8 m49.8 m187.3 m

Accounts Receivable

48 k933 k


1.5 m2.6 m2.2 m

Current Assets

110.5 m141 m296.3 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


27.9 m76.2 m66.7 m43.4 m46.2 m65.8 m87.3 m

Accounts Receivable

74 k48 k14 k

Current Assets

102.7 m155 m158.8 m219.5 m192.5 m165.1 m255.1 m


404 k398 k479 k629 k1.8 m2.7 m2.9 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(37 m)(60.7 m)(135.7 m)

Depreciation and Amortization

49.4 k96 k296 k

Accounts Receivable

87 k


(773 k)(1 m)428 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.7 m)(10.7 m)(19.5 m)(25.8 m)(35.8 m)(36.3 m)(44.5 m)

Accounts Receivable

114 k57 k74 k48 k14 k

Accounts Payable

1.5 m3 m4.3 m2.4 m5.3 m2.4 m5.1 m8.5 m15.1 m
Y, 2017

Financial Leverage

8.5 x
Show all financial metrics

Akebia Therapeutics Market Value History

Akebia Therapeutics Job Categories

Traffic Overview of Akebia Therapeutics

Akebia Therapeutics Online and Social Media Presence

Akebia Therapeutics Company Life and Culture

You may also be interested in